Stryker (SYK) Stock Forecast & Price Target

Stryker is viewed as a core MedTech holding because its broad portfolio, market-leading orthopedic robotics, and leadership in operating room equipment support durable share gains and consistent outperformance versus end-market growth. The company’s guidance points to FY26 organic sales growth of +8.0-9.5%, adjusted diluted EPS of $14.90-15.10, and management expects +150 bps of EBIT margin expansion from FY26-28, reinforcing an attractive earnings and margin trajectory. With roughly one-fourth of revenue outside the United States, plus international expansion, innovation, and accretive M&A, its exposure to higher-growth end markets should sustain robust free cash flow and double-digit EPS growth.

Stryker is facing a more challenged 2H26 setup as Peripheral Vascular supply and manufacturing issues tied to the March 11 cyber event are persisting longer than expected, while Joint Replacement is seeing softer U.S. summer demand and continued European weakness. These pressures are lowering 2026 organic revenue growth to about 8.0%-8.3%, leaving it at or below the low end of the 8.3%-9.3% guide and pushing adjusted EPS estimates to roughly $14.92-$14.96, near the bottom of the $14.95-$15.10 range. Beyond the near term, competitive risk in orthopedic robotics, slower ASC adoption, product-cycle maturity, and uncertainty around M&A execution increase the likelihood that growth and margins remain under pressure even after the current disruptions ease.